Inhibition of vascular endothelial growth factor expression by TRUE gene silencing.
Pathogenic angiogenesis in various diseases including cancer, autoimmune diseases, and age-related macular degeneration is thought to be regressed with anti-angiogenic drugs. TRUE gene silencing is a new technology to eliminate a specific mRNA using synthetic sgRNA and cellular tRNase Z(L). To discover anti-angiogenic sgRNAs, we applied TRUE silencing to the VEGF gene. We examined eight sgRNAs for efficacy in targeting exogenous human VEGF mRNA. Many of them worked efficiently in 293 and HeLa cells. Two of them downregulated the endogenous VEGF gene expression in HeLa cells very efficiently, and the efficacy of these two sgRNAs surpassed that of siRNA extremely.
Elbarbary
Reyad A
RA
Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Niigata, Niigata 956-8603, Japan.
Takaku
Hiroaki
H
Tamura
Masato
M
Nashimoto
Masayuki
M
D001483:Base Sequence; D015536:Down-Regulation; D004722:Endoribonucleases / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D020868:Gene Silencing; D006367:HeLa Cells; D006801:Humans; D008969:Molecular Sequence Data; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000628:therapy; D009690:Nucleic Acid Conformation; D012333:RNA, Messenger / Q000737:chemistry / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000235:genetics*; D058727:RNA, Small Untranslated
D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D004722:Endoribonucleases; C531011:tRNase Z, human; D058727:RNA, Small Untranslated